Lupin Introduces Generic Pred Forte in United States
Overview
Global pharma major Lupin Limited (Lupin) announced the launch of the first generic version of Pred Forte (prednisolone acetate) ophthalmic suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity.
The Suspension
Prednisolone acetate ophthalmic suspension USP, 1% is a generic equivalent of Pred Forte ophthalmic suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Pred Forte had estimated annual sales of USD 198 million in the US (IQVIA MAT August 2024).
Words from the CEO: Lupin
"The launch of prednisolone acetate ophthalmic suspension is a milestone and is aligned with our commitment to enhancing access to innovative, affordable and quality healthcare solutions,"" said Vinita Gupta, CEO, Lupin.
“This will strengthen our ophthalmic portfolio and will benefit patients seeking effective treatment for steroid-responsive inflammation."
About the Company: Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets.
Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.